Safety effect of fermented oyster extract on the endocrine disruptor assay in vitro and in vivo
- Authors
- Hyesook Lee; Hyun Hwang-Bo; Seon Yeong Ji; Seyeon Oh; Kyung-A Byun; Joung-Hyun Park; Bae-Jin Lee; Gi Young Kim; Yung Hyun Choi
- Issue Date
- Oct-2021
- Publisher
- 한국수산과학회
- Keywords
- androgen; endocrine disruptor; estrogen; fermented oyster (FO); reproductive toxicity
- Citation
- Fisheries and Aquatic Sciences, v.24, no.10, pp.330 - 339
- Journal Title
- Fisheries and Aquatic Sciences
- Volume
- 24
- Number
- 10
- Start Page
- 330
- End Page
- 339
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82967
- DOI
- 10.47853/FAS.2021.e32
- ISSN
- 2234-1757
- Abstract
- Oyster (Crassostrea gigas) is a marine bivalve mollusk widely distributed in coastal areas, and have been long widely used in industrial resources. Several studies demonstrated that fermented oyster (FO) extract attribute to bone health, but whether administration of FO play as an endocrine disruptor has not been studied. Therefore, in the present study, we investigated the effect of FO on the endocrine system in vitro and in vivo. As the results of the competitive estrogen receptor (ER) and androgen receptor (AR) binding affinities, FO was not combined with ER-α, ER-β, and AR. However, 17β-estradiol and testosterone, used as positive control, were interacted with ER and AR, respectively. Meanwhile, oral administration of 100 mg/kg and 200 mg/kg of FO doesn’t have any harmful effect on the body weight, androgen-dependent sex accessory organs, estrogen-dependent-sex accessory organs, kidney, and liver in immature rats. In addition, FO supplementation has no effect on the serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, and 17β-estradiol. However, the relative weight of androgen- and estrogen-dependent organs were significantly increased by subcutaneously injection of 4.0 mg/kg of testosterone propionate (TP) and by orally administration of 1.0 μg of 17α-ethynyl estradiol (EE) in immature male and female rats, respectively.
Furthermore, TP and EE administration markedly decreased the serum LH and FSH levels, which are similar those of mature Sprague-Dawley (SD) rat. Furthermore, the testosterone and 17β-estradiol levels were significantly enhanced in TP and EE-treated immature rats. Taken together, our findings showed that FO does not interact with ER and AR, suggesting consequentially FO does not play as a ligand for ER and AR. Furthermore, oral administration of FO did not act as an endocrine disruptor including androgenic activity, estrogenic activity, and abnormal levels of sex hormone, indicating FO may ensure the safety on endocrine system to develop dietary supplement for bone health.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82967)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.